灯盏生脉胶囊在缺血性脑卒中患者二级预防中的应用效果

Application Effects on the Seeondary Prevention for Isehemic Stroke by Erigeron Shengmai Capsule

目的探讨灯盏生脉胶囊在缺血性脑卒中患者二级预防中的疗效。方法整群选取2014年2月—2015年3月在该院神经内科收治的126例缺血性脑卒中恢复期患者采用随机数字表法分为对照组(n=63)和观察组(n=63),两组患者均参照指南给予常规基础治疗口服阿司匹林肠溶片100 mg,1次/d,对阿司匹林不能耐受者可口服氯吡格雷75mg,1次/d,连续治疗6个月;观察组在此基础上给予灯盏生脉胶囊治疗,2粒/次,3次/d,疗程为6个月。6个月后对照分析两组的神经功能恢复状况(NIHSS)、日常生活活动能力(Barthel指数)、运动功能(FMI)、致残率(m RS)、病死率、生存质量(SS-QOL)、复发率、纤维蛋白原(Fbi)及血脂等指标。结果随访6个月后,观察组患者治疗后的NIHSS评分(9.08±4.37)、Barthel指数(88.36±18.68)、FMI评分(89.51±21.37)、SS-QOL(398.25±78.54)评分、血浆Fib(3.27±0.51)g/L、TC(5.27±0.82)mmo/L、TG(2.32±0.37)mmo/L和LDL-C(2.39±0.37)mmo/L均显著低于治疗前(P<0.05),而观察组明显低于对照组(P<0.05);两组治疗后的m RS评分(1.16±1.25)明显低于治疗前(P<0.05),但组间比较差异无统计学意义(P>0.05);两组患者治疗前后的HDL-C(1.29±0.41)mmo/L比较差异无统计学意义(P>0.05);两组的复发率和病死率比较差异无统计学意义(P>0.05)。结论缺血性脑卒中患者采用灯盏生脉胶囊联合西药进行二级预防,效果明显优于单纯西药。

Objective To study the effects on the secondary prevention for isehemic stroke by Erigeron Shengmai capsule. Methods 126 patients with isehemic stroke were randomly divided into routine control group （n=63）and observation group （n=63）. Two groups were given regular basis treatment with reference guide,observation group was given Erigeron Shengmai capsule, 2/time, 3 times/d,these drugs were continuous treatment for 6 months. Neurologic recovery state （NIHSS）, daily life activities ability （Barthel index） ,motor function （FMI）, morbidity （mRS） , mortality , quality of life （SS-QOL）, recurrence rate,fibrinogen （Fbi） and blood lipids of control group and observation group were compared after treatment for 6 months. Results NIHSS score,Barthel index,FMI score, SS-QOL score,plasma Fib,TC,TG and LDL-C of two groups werc significantly lower than before treatment （P〈O.05）,but those of observation group were significantly lower than the control group （P〈0.05）. mRS score of two groups after treatment were significantly lower than befi）re treatment（P〈0.05）,but there was no statistically significant difference between control group and observation group （P〉0.05）. HI）L-C,recurrence rate and case fatality rate of two groups was no statistical significance between before and after treatment （P〉0.05）. Conclusion The ef- feets of Erigeron Shengumi capsule combined western medicine on the secondary prevention for isehemic stroke are better than pure western medicine.